Zymeworks removes CFO Christopher Astle effective March 31; severance $425,000

Zymeworks Inc.

Astle removed as CFO and principal accounting officer without cause, effective March 31, 2024.
Severance package includes $425,000 lump sum (12 months' base salary) and 12 months of health benefits.
Astle retains 92,369 vested stock options (90 days to exercise); 146,881 unvested options and 51,000 unvested RSUs forfeited.
CEO Kenneth Galbraith serves as interim CFO; no permanent replacement announced.
Separation agreement includes non-solicitation, non-competition, and confidentiality covenants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Astle

Senior Vice President and Chief Financial Officer

ZYME · Zymeworks Inc.

Effective: 2024-03-31
Filed: April 4, 2024, 7:59 PM ET

As previously reported, effective March 31, 2024 (the “Separation Date”), Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..

Action: removed
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

As previously reported, effective March 31, 2024 (the “Separation Date”), Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-086214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.